Company profile: AnPac Bio
1.1 - Company Overview
Company description
- Provider of early cancer screening and detection services, offering the CDA Early Cancer Risk Assessment using Cancer Differentiation Analysis to evaluate early cancer risks, the APCS Pan-Cancer Screening to detect multiple cancer types, and the ADME Third Immune Defense Test to assess immune defense capabilities against diseases, including cancer.
Products and services
- ADME Third Immune Defense Test: Offers an immune-defense test that evaluates individuals’ immune system defense capabilities against diseases, including cancer
- APCS Pan-Cancer Screening: Delivers a pan-cancer screening service designed to detect multiple types of cancer in individuals, enabling broad early identification across malignancies
- CDA Early Cancer Risk Assessment: Supplies a CDA-based cancer risk assessment service that evaluates early cancer risks in individuals using Cancer Differentiation Analysis technology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AnPac Bio
Craniovation
HQ: United States
Website
- Description: Provider of a minimally invasive light-delivery device to treat aggressive brain tumors, including those deep within the brain, allowing patients to avoid invasive brain surgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Craniovation company profile →
Sofie
HQ: United States
Website
- Description: Provider of molecular imaging, focused on empowering people with new PET technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sofie company profile →
Emergence Therapeutics
HQ: Germany
Website
- Description: Provider of novel antibody-drug conjugate (ADC) immunotherapies for high-need cancers, developing programs that combine highly specific antibodies with optimized linker and payload technology; lead program targets Nectin-4, a clinically validated target across a broad range of cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emergence Therapeutics company profile →
Coordination Pharma
HQ: United States
Website
- Description: Provider of nanoparticle-based anticancer therapies, including CPI-100, which delivers immunostimulatory chemotherapeutic combinations directly to tumors. Offers the NCP platform using nanoscale coordination polymers to develop products targeting solid tumors, and seeks partnership opportunities to enhance current cancer immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coordination Pharma company profile →
Morphic Therapeutics
HQ: United States
Website
- Description: Provider of oral integrin therapies in development to treat serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer; developing treatments for patients with immunological, fibrotic, neoplastic, and vascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Morphic Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AnPac Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AnPac Bio
2.2 - Growth funds investing in similar companies to AnPac Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AnPac Bio
4.2 - Public trading comparable groups for AnPac Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →